Weather Alert
Snow is in the forecast. Consider switching to a virtual visit to receive care from home. Learn more >>
Popular Search Terms
Susanne Baumeister, MD
Clinical Director, Cellular Immunotherapy Program
Assistant Professor of Pediatrics, Harvard Medical School
Image
Susanne Baumeister, MD
Clinical Director, Cellular Immunotherapy Program
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Ludwig-Maximilians-Universitaet
Munich
Germany
Residency
University of Washington / Seattle Children's Hospital
Seattle
WA
Fellowship
Boston Children's Hospital / Dana Farber Cancer Institute
Boston
MA
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Publications
Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. View Abstract
B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. View Abstract
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. View Abstract
Mediport use as an acceptable standard for CAR T cell infusion. View Abstract
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. View Abstract
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. View Abstract
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. View Abstract
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. View Abstract
Getting (T cells) ENGaged. View Abstract
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. View Abstract
Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. View Abstract
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. View Abstract
Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. View Abstract
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. View Abstract
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. View Abstract
Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. View Abstract
Coinhibitory Pathways in Immunotherapy for Cancer. View Abstract
Contribution of CD8+ T cells to containment of viral replication and emergence of mutations in Mamu-A*01-restricted epitopes in Simian immunodeficiency virus-infected rhesus monkeys. View Abstract
Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. View Abstract
G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity. View Abstract
Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. View Abstract